IL6 and nonpapillary renal cell carcinoma: Numerous new IL-6/JAK/STAT3 pathway inhibitors have been identified to date and are currently undergoing preclinical and/or clinical evaluation (Oh et al., 2015; Liu et al., 2016), whereas few studies were reported on IL6-JAK-STAT3 pathway signature in ccRCC.